{[2-(acetylamino)-1,3-thiazol-4-yl]methyl}(triphenyl)phosphonium chloride | 874899-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {[2-(acetylamino)-1,3-thiazol-4-yl]methyl}(triphenyl)phosphonium chloride
• 英文别名: [(2-acetamido-1,3-thiazol-4-yl)methyl](triphenyl)phosphonium chloride；[(2-acetylaminothiazol-4-yl)methyl](triphenyl)phosphonium chloride；[(2-Acetylaminothiazol-4-yl)methyl](triphenyl)phosphonium chloride；(2-acetamido-1,3-thiazol-4-yl)methyl-triphenylphosphanium;chloride
• CAS: 874899-73-7
• 化学式: C₂₄H₂₂N₂OPS*Cl
• 分子量: 452.944
• InChiKey: ITPGGUNSUDNGRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {[2-(acetylamino)-1,3-thiazol-4-yl]methyl}(triphenyl)phosphonium chloride 在 palladium 10% on activated carbon 、 potassium tert-butylate 、 氢气 、 溶剂黄146 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、405.33 kPa 条件下， 反应 18.25h， 生成 N-[4-(2-{4-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]phenyl}ethyl)-1,3-thiazol-2-yl]acetamide
  参考文献：
  名称：

  Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema

  摘要：

  Vascular adhesion protein-1 (VAP-1), an amine oxidase that is also known as a semicarbazide-sensitive amine oxidase (SSAO), is present in particularly high levels in human plasma, and is considered a potential therapeutic target for various inflammatory diseases, including diabetes complications such as macular edema.In our VAP-1 inhibitor program, structural modifications following high-throughput screening (HTS) of our compound library resulted in the discovery that thiazole derivative 10, which includes a guanidine group, shows potent human VAP-1 inhibitory activity (IC50 of 230 nM; rat IC50 of 14 nM). Moreover, compound 10 exhibited significant inhibitory effects on ocular permeability in STZ-induced diabetic rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.12.025
• 作为产物：
  描述：

  2 -乙酰氨基- 4-(氯甲基)-1,3-噻唑 、 三苯基膦 在 异丙醚 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 12.0h， 以to give [(2-acetylaminothiazol-4-yl)methyl](triphenyl)phosphonium chloride (35.7 g) as colorless powder的产率得到{[2-(acetylamino)-1,3-thiazol-4-yl]methyl}(triphenyl)phosphonium chloride
  参考文献：
  名称：

  Thiazole Derivatives Having Vap-1 Inhibitory Activity

  摘要：

  化合物的结构式（I）：U-V-W-X-Y-Z  （I），其中U为低级烷基；V为—CONH—或—NR1CO—，其中R1为氢或低级烷基；W为键或低级亚烷基；X为源自可选取代噻唑的二价残基；Y为键或低级亚烷基；Z为下式的基团：其中R2为下式的基团：-A-B-D-E-F-G，其中A为键或低级亚烷基；B为键，—NH—或D为键，—CS—或—CO—；E为键或—NH—；F为键，—CO—，—O—或—SO2—；G为低级烷基，可选的保护氨基，—OH，苯基，R3为低级烷基，但当Z为下式的基团时：则G不应为氨基；当Z为下式的基团时：则G不应为；当Z为下式的基团时：若G为可选的保护氨基，则D应为—CS—，或者A应为低级亚烷基，B或E应为—NH—，F应为—CO—；或其药学上可接受的盐，作为血管黏附蛋白-1（VAP-1）抑制剂以及用于预防或治疗VAP-1相关疾病，特别是黄斑水肿的制剂组合物和方法，该方法包括向受体施用化合物或其药学上可接受的盐的有效量等。

  公开号：

  US20080015202A1

文献信息

• [EN] THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR<br/>[FR] DÉRIVÉ DE THIAZOLE ET SON UTILISATION EN TANT QU'INHIBITEUR DE LA VAP-1
  申请人：R TECH UENO LTD

  公开号：WO2009096609A1

  公开（公告）日：2009-08-06

  The present invention provides a novel thiazole derivative useful as a VAP-1 inhibitor, a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型噻唑衍生物，可作为VAP-1抑制剂，用于预防或治疗与VAP-1相关的疾病等的药用剂。一种由以下式（I）表示的化合物：其中每个符号如规范中定义，或其药用可接受的盐。
• Thiazole derivative and use thereof as VAP-1 inhibitor
  申请人：Matsukawa Tatsuya

  公开号：US08507690B2

  公开（公告）日：2013-08-13

  The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R1—NH—X—Y—Z wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种噻唑衍生物，可用作VAP-1抑制剂，以及用于预防或治疗VAP-1相关疾病等的药物，一种抑制主体中VAP-1的方法，以及一种预防或治疗主体中VAP-1相关疾病的方法。该噻唑衍生物是由式(I)表示的化合物：R1—NH—X—Y—Z，其中每个符号如规范中所定义，或其药学上可接受的盐。
• THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR
  申请人：Matsukawa Tatsuya

  公开号：US20110015240A1

  公开（公告）日：2011-01-20

  The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R 1 —NH—X—Y—Z wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种噻唑衍生物，可用作VAP-1抑制剂，以及用于预防或治疗VAP-1相关疾病等的药物，用于在受体中抑制VAP-1的方法以及用于预防或治疗受体中VAP-1相关疾病的方法。该噻唑衍生物是由式（I）表示的化合物：R1-NH-X-Y-Z，其中每个符号如规范中所定义，或其药学上可接受的盐。
• Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment
  作者：Takayuki Inoue、Masataka Morita、Takashi Tojo、Akira Nagashima、Ayako Moritomo、Hiroshi Miyake

  DOI：10.1016/j.bmc.2013.04.011

  日期：2013.7

  Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although we previously identified a compound (2) with potent VAP-1 inhibitory activity in rats, the human activity was relatively weak. Here, to improve the human VAP-1 inhibitory activity of compound 2, we first evaluated the structure-activity relationships of guanidine bioisosteres as simple small molecules and identified a 1H-benzimidazol-2-amine (5) with potent activity compared to phenylguanidine (1). Based on the structure of compound 5, we synthesized a highly potent VAP-1 inhibitor (37b; human IC50 = 0.019 mu M, rat IC50 = 0.0051 mu M). Orally administered compound 37b also markedly inhibited ocular permeability in streptozotocin-induced diabetic rats after oral administration, suggesting it is a promising compound for the treatment of diabetic macular edema. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
• [EN] THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY<br/>[FR] DERIVES DE THIAZOLE PRESENTANT UNE ACTIVITE D'INHIBITION DE LA VAP-1
  申请人：ASTELLAS PHARMA INC

  公开号：WO2006011631A3

  公开（公告）日：2006-04-20